Iloprost Ratiopharm (Iloprost)

Iloprost acts as an agonist at prostacyclin (IP) receptors on vascular smooth‑muscle cells, stimulating cyclic AMP production. This leads to vasodilation, reduced pulmonary vascular resistance, and inhibition of platelet aggregation, improving blood flow in affected vessels.

The dosing regimen for Iloprost Ratiopharm is individualized and set by the prescribing physician based on the patient’s condition, response, and tolerance. Specific dose and infusion duration are determined by the treating clinician.

Safety data for Iloprost in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Iloprost is a prostacyclin analog, providing direct vasodilation and antiplatelet effects, whereas endothelin receptor antagonists block vasoconstrictive pathways and phosphodiesterase‑5 inhibitors enhance nitric‑oxide signaling. Choice of therapy depends on disease severity, patient tolerance, and physician assessment.

Iloprost Ratiopharm should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze the solution and avoid shaking the vial, as physical agitation can affect product stability.

Iloprost Ratiopharm is supplied as an intravenous solution that is administered by a healthcare professional through a controlled infusion pump. The infusion rate and duration are set according to the prescribing physician’s instructions.

The most serious risks include severe hypotension, pulmonary edema, and bleeding complications, especially when used with anticoagulants. Patients should be monitored closely for signs of cardiovascular instability and respiratory distress.

Iloprost is contraindicated in patients with active bleeding, severe coronary artery disease, uncontrolled hypotension, or known hypersensitivity to iloprost or any component of the formulation. It should also be used with caution in individuals with pulmonary edema or recent myocardial infarction.